Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-26

Reporting Person: FIL Ltd (See Remark 1)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-26	Common Stock	C	218705	—	Acquired	218705	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-26	Series B Preferred Stock	$	C	2077698	Disposed		Common Stock (218705)	Indirect

Footnotes

F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.